Does Rallies show Form 4 insider transactions for LCTX?

Yes. Rallies tracks LCTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LCTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LCTX. It does not provide personalized investment advice.

LCTX (Lineage Cell Therapeutics, Inc.) Stock Analysis - Insider Trades

Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded Healthcare sector company. As of May 20, 2026, LCTX trades at $1.31 with a market cap of $309.13M and a P/E ratio of -4.38. LCTX moved +8.75% today. Year to date, LCTX is -26.83%; over the trailing twelve months it is +141.25%. Its 52-week range spans $0.37 to $2.09. Analyst consensus is strong buy with an average price target of $6.25. Rallies surfaces LCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LCTX stock inside the company?

Recent LCTX insider activity includes Culley Brian M bought 15.00K, BROADWOOD PARTNERS, L.P. bought 7.89M, Howe Jill Ann bought 15.00K, Samuel George A. III bought 15.00K, and Mulroy Michael H. bought 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LCTX Key Metrics

Key financial metrics for LCTX
Metric	Value
Price	$1.31
Market Cap	$309.13M
P/E Ratio	-4.38
EPS	$-0.28
Dividend Yield	0.00%
52-Week High	$2.09
52-Week Low	$0.37
Volume	1.42M
Avg Volume	0
Revenue (TTM)	$14.78M
Net Income	$-64.01M
Gross Margin	0.00%

Recent LCTX Insider Trades

Culley Brian M bought 15.00K (~$24.38K) on Mar 12, 2026.
BROADWOOD PARTNERS, L.P. bought 7.89M (~$6.00M) on Jan 27, 2025.
Howe Jill Ann bought 15.00K (~$8.85K) on Nov 26, 2024.
Samuel George A. III bought 15.00K (~$9.00K) on Nov 26, 2024.
Mulroy Michael H. bought 40.00K (~$22.64K) on Nov 22, 2024.

Latest LCTX News

Lineage Cell Therapeutics Poised for $20B Cell Therapy Market Expansion — May 20, 2026
Lineage Cell Q1 Loss Widens to $0.03, Revenue Misses Estimates — May 12, 2026
Lineage Advances AlloSCOPE for Type 1 Diabetes, Hits First Roche Milestone — Apr 10, 2026
Lineage Cell Secures $5M Roche Milestone as GALE Trial Expands to 17 Sites — Mar 6, 2026
Lineage Cell posts break-even EPS and 130% revenue growth in Q4 — Mar 5, 2026

LCTX Analyst Consensus

4 analysts cover LCTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.25.

Common questions about LCTX

Who is trading LCTX stock inside the company?: Recent LCTX insider activity includes Culley Brian M bought 15.00K, BROADWOOD PARTNERS, L.P. bought 7.89M, Howe Jill Ann bought 15.00K, Samuel George A. III bought 15.00K, and Mulroy Michael H. bought 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LCTX?: Yes. Rallies tracks LCTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LCTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LCTX. It does not provide personalized investment advice.